Abstract:Presently, clinically approved adjuvants (such as aluminum salts) fail to induce cellular immune responses, which is crucial to defend against intracellular pathogens (including HIV, malaria, tuberculosis and Ebola) and cancer. However, Freund's complete adjuvant potently stimulates both humoral and cellular immune responses, accompanying by high toxicity and severe side reactions. Here in this work, a CpG-oligodeoxynucleotides (CpG-OND) crosslinked aminated beta-glucan-Ovalbumin dual targeting nanoparticle (CpG-OND-AG-OVA) is prepared through a simple and mild ionic complexation method. The aminated beta-glucan plays dual roles as antigen presenting cells (APCs) targeted carrier and immunopotentiator (targeting and activating dectin-1 on APCs). Meanwhile, CpG-OND also plays dual roles as ionic crosslinker and immunopotentiator (targeting and activating Toll-like receptor 9 in APCs). The adjuvant activity of the particles is evaluated through in vitro and in vivo experiments. The particles significantly enhance uptake and sustained proteolytic processing of antigens, and result in APCs maturation, inducing robust Th1 and Th2-type immune responses comparable to Freund's adjuvant without obvious toxicity. The potent adjuvant activity of the nanoparticles may originate from dual targeting synergistic effects between aminated beta-glucan and CpG-OND. Accordingly, the dual targeting nanoparticles may be a promising vaccine adjuvant for inducing robust humoral and cellular immune responses against infectious diseases and cancers. Statement of Significance An ideal adjuvant for subunit vaccine should act as both a carrier to enhance the uptake, sustained processing and cytosolic delivery of antigens, and an immunopotentiator to stimulate antigen presenting cells (APCs) for activation of naive T cells. Additionally, it should be easy to obtain and safe with negligible toxicity. Unfortunately, both synthetic and natural polymers that have been developed into antigen delivery system cannot completely fulfill the requirements. In the present study, the authors design nanoparticles with aminated beta-glucan and CpG-oligodeoxynucleotides (CpG-OND) through a simple and mild method. beta-Glucan (a dectin-1 and TLR2 targeted PAMP) and CpG-OND (a TLR9 targeted PAMP) are readily accessible. Aminated beta-glucan plays dual roles in the nanoparticle as APCs targeted carrier and immunopotentiator. Meanwhile, CpG-OND also plays dual roles as crosslinker and APCs targeted immunopotentiator. By making use of synergistic effect of the dual targeting vaccine adjuvant with aminated beta-glucan and CpG-OND, the nanoparticles induce robust antigen specific immune responses comparable to Freund's adjuvant without obvious toxicity. (C) 2018 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Synergistic immune augmentation enabled by covalently conjugating TLR4 and NOD2 agonists

Codelivery of Nod2 and Tlr9 Ligands Via Nanoengineered Protein Antigen Particles for Improving and Tuning Immune Responses

Co-delivery of antigen and dual adjuvants by aluminum hydroxide nanoparticles for enhanced immune responses

Covalently Conjugated NOD2/TLR7 Agonists Are Potent and Versatile Immune Potentiators

Conjugation of TLR7 and TLR7/8 agonists onto weak protein antigen via versatile oxime ligation for enhanced vaccine efficacy

The synthesis and preliminary immunological evaluation of a dual-adjuvant SARS-CoV-2 RBD vaccine: Covalent integration of TLR7/8 and iNKT cell agonists

Synergistic Effect of Dual Targeting Vaccine Adjuvant with Aminated Β-Glucan and CpG-oligodeoxynucleotides for Both Humoral and Cellular Immune Responses

Co-adjuvanting Nod2-stimulating bacteria with a TLR7 agonist elicits potent protective immunity against respiratory virus infection

A Polymer-Based Antigen Carrier Activates Two Innate Immune Pathways for Adjuvant-Free Subunit Vaccines

TLR9 and STING Agonists Cooperatively Boost the Immune Response to SARS-CoV-2 RBD Vaccine Through an Increased Germinal Center B Cell Response and Reshaped T Helper Responses

Synthesis and Evaluation of Conjugates of Novel TLR7 Inert Ligands As Self-Adjuvanting Immunopotentiators.

A Unique Combination of Mn2+ and Aluminum Adjuvant Acted the Synergistic Effect

Dual TLR Agonist Nanodiscs As a Strong Adjuvant System for Vaccines and Immunotherapy

Strategic Development of a Self-Adjuvanting SARS-CoV-2 RBD Vaccine: from Adjuvant Screening to Enhanced Immunogenicity with a Modified TLR7 Agonist

Synthetic Innate Defense Regulator Peptide Combination Using Cpg Odn As A Novel Adjuvant Induces Long-Lasting and Balanced Immune Responses

Human In vitro Modeling Identifies Adjuvant Combinations that Unlock Antigen Cross-presentation and Promote T-helper 1 Development in Newborns, Adults and Elders

STING and TLR9 agonists synergistically enhance the immunogenicity of SARS-CoV-2 subunit vaccine

Dictating the spatial-temporal delivery of molecular adjuvant and antigen for the enhanced vaccination

A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7

Synergistic Immunostimulation through the Dual Activation of Toll-like Receptor 3/9 with Spherical Nucleic Acids

Conjugation of Weak Ligands with Weak Antigens to Activate TLR-7: A Step Toward Better Vaccine Adjuvants.